Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Hepatitis B, Chronic
Interventions
DRUG

entecavir

Tablets, Oral, 1 mg, once daily, up to 72 weeks

Trial Locations (32)

112

Local Institution, Taipei

833

Local Institution, Kaohsiung City

3084

Local Institution, Heidelberg

4102

Local Institution, Woolloongabba

14642

University Of Rochester Medical Center, Rochester

40125

Local Institution, Bologna

44195

Cleveland Clinic, Cleveland

45267

University Of Cincinnati Medical Center, Cincinnati

46009

Local Institution, Valencia

55905

Mayo Clinic, Rochester

60020

Local Institution, Torrette Di Ancona

60430

Local Institution, Fortaleza

60611

Northwestern University, Chicago

68198

University Of Nebraska Medical Center, Omaha

70112

Tulane University Hospital & Clinic, New Orleans

75246

Baylor University Medical Center, Dallas

75571

Local Institution, Paris

77030

Baylor College Of Medicine, Houston

90035

Local Institution, Porto Alegre

92118

Local Institution, Clichy

94800

Local Institution, Villejuif

280009

Local Institution, Madrid

C1181ACH

Local Institution, Buenos Aires

01246

Local Institution, São Paulo

00133

Local Institution, Roma

00168

Local Institution, Roma

110-744

Local Institution, Seoul

120-752

Local Institution, Seoul

135-710

Local Institution, Seoul

138-736

Local Institution, Seoul

08035

Local Institution, Barcelona

08036

Local Institution, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY